Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix® On-Demand Webinar Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix® Watch our on-demand webinar on empiric PK time-course scaling and learn how Certara’s translational experts…Certara2025 年 11 月 13 日
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema Publication Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…Certara2025 年 11 月 12 日
Supporting KalVista’s NDA Submission for a Novel HAE Treatment Case Study Supporting KalVista’s NDA Submission for a Novel HAE Treatment To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…Danielle Pillsbury2025 年 11 月 12 日
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Case Study Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…Certara2025 年 11 月 10 日
Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns On-Demand Webinar Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns In today’s market where long development timelines and investor caution can slow progress, MIDD offers…Certara2025 年 11 月 10 日
Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient On-Demand Webinar Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient Watch the on-demand webinar on avoiding drug launch failure. Learn how smarter development, evidence, and…Certara2025 年 11 月 6 日
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation Publication Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation This study demonstrates how model-informed approaches can improve dose selection decisions when direct clinical comparisons…Certara2025 年 11 月 5 日
Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights On-Demand Webinar 按时交付:借助定量药理学分析洞见,顺利推进监管申报 Watch this on-demand webinar to learn how pharmacometrics supports NDA, BLA, and global regulatory submissions.…Certara2025 年 11 月 3 日
AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success On-Demand Webinar AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…Certara2025 年 10 月 21 日
Streamlining PK/PD reporting: A smarter approach to generating tables, figures and listings Blog Streamlining PK/PD reporting: A smarter approach to generating tables, figures and listings Discover how TFL Studio accelerates PK/PD reporting. Create audit-ready tables, figures, and listings faster with…Certara2025 年 10 月 16 日